(WJW) – A nationwide recall on thyroid tablets has now been classified as one the U.S. Food and Drug Administration’s most serious and urgent recalls.

According to the recall alert, which was first announced in August, there were concerns that the medication could be overly potent and potentially cause symptoms related to an overactive thyroid.


Discover more local reporting on our homepage

On Wednesday, the FDA updated the recall, listing it as Class I, which is defined as a situation in which there is a “reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”

In August, Vitruvias Therapeutics Inc. voluntarily recalled one lot of its Thyroid Tablets after testing confirmed the potential for the product to be “superpotent.”

The statement warned that superpotent Thyroid tablets can cause hyperthyroidism (overactive thyroid) including symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances.

Elderly people, pregnant women, and infants, are at greater risk of adverse effects, especially over extended periods of time, warned the recall.

Here’s what to check for:

ProductNDCLotExp DateUnits 
ReleasedUnits 
SoldFirst 
Distribution 
DateLast 
Distribution 
Date Thyroid 
Tablets, 
USP 30 mg 69680- 
166-00 504950 9/30/2026 3,655 1,955 1/31/2025 9/30/2025

At the time of the initial recall, patients were advised that they shouldn’t stop using the medication without contacting their health care provider for further guidance or a replacement prescription.

Consumers with questions about the recall can contact Vitruvias Therapeutics, Inc. by email at safety@vitruvias.com or by phone at (256) 239-9373 Monday through Friday from 9 a.m. to 5 p.m. CT.

Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking the medication.